• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca PLC – ADR to Join the NASDAQ-100 Index Beginning February 22, 2022

    2/10/22 5:00:00 PM ET
    $AZN
    $NDAQ
    $XLNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $AZN alert in real time by email

    NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that AstraZeneca PLC – ADR (NASDAQ:AZN), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX) and the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) prior to market open on Tuesday, February 22, 2022. AstraZeneca PLC – ADR will replace Xilinx, Inc. (NASDAQ:XLNX) in the NASDAQ-100 Index® and the NASDAQ-100 Equal Weighted Index.

    For more information about the company, go to https://www.astrazeneca.com.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

    Media Contact

    Emily Pan

    [email protected]

    +1 (646) 637-3964

    Issuer & Investor Contact

    Index Client Services

    [email protected]

    The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither The NASDAQ OMX Group, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq's proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    - NDAQG -



    Primary Logo

    Get the next $AZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $NDAQ
    $XLNX

    CompanyDatePrice TargetRatingAnalyst
    Nasdaq Inc.
    $NDAQ
    7/25/2025$115.00Neutral → Buy
    UBS
    Nasdaq Inc.
    $NDAQ
    4/17/2025$91.00Neutral → Buy
    Redburn Atlantic
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    Nasdaq Inc.
    $NDAQ
    4/8/2025$74.00Overweight → Equal-Weight
    Morgan Stanley
    AstraZeneca PLC
    $AZN
    2/13/2025Neutral → Buy
    UBS
    AstraZeneca PLC
    $AZN
    2/12/2025Overweight
    Morgan Stanley
    Nasdaq Inc.
    $NDAQ
    1/8/2025$80.00 → $98.00Hold → Buy
    Deutsche Bank
    Nasdaq Inc.
    $NDAQ
    11/25/2024Outperform
    William Blair
    More analyst ratings

    $AZN
    $NDAQ
    $XLNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zollar Alfred W bought $203,970 worth of shares (2,542 units at $80.24), increasing direct ownership by 5% to 49,293 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    11/14/24 4:29:16 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Torgeby Johan bought $705,880 worth of shares (14,000 units at $50.42), increasing direct ownership by 165% to 22,466 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    10/25/23 4:02:10 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date September 30, 2025

    NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of September 30, 2025, short interest in 3,366 Nasdaq Global MarketSM securities totaled 14,078,324,727 shares compared with 14,035,983,054 shares in 3,341 Global Market issues reported for the prior settlement date of September 15, 2025. The mid-September short interest represents 2.16 days compared with 2.49 days for the prior reporting period. Short interest in 1,675 securities on The Nasdaq Capital MarketSM totaled 3,220,349,947 shares at the end of the settlement date of September 30, 2025, compared with 3,110,176,592 shares in 1,673 securities for the previous reporting period. This represents a 1.00 day a

    10/9/25 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

    New manufacturing facility to be located near Charlottesville, in Albemarle County, Virginia will develop and manufacture a broader range of medicines including weight management, metabolic and cancer technologies Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America AstraZeneca today announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at Rivanna Futures in Albe

    10/9/25 12:30:00 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery

    LONDON, UK and BUDAPEST, HUNGARY, Oct. 9, 2025 /PRNewswire/ -- Turbine, a leading company specializing in virtualizing biological experiments with AI, today announced a collaboration with AstraZeneca (NASDAQ:AZN) to test the ability of Turbine's platform to rationalize antibody-drug conjugate (ADC) discovery by predicting response mechanisms, informing ADC positioning, and reducing the need for large-scale cell line screens. This collaboration will apply Turbine's platform, which virtualizes biological experiments at scale, to not only improve the efficiency and speed of ADC discovery but also deliver mechanistic insights that current experimental screening approaches may typically lack.

    10/9/25 6:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CSO Skule Jeremy sold $185,703 worth of shares (2,105 units at $88.22) and covered exercise/tax liability with 1,262 shares, decreasing direct ownership by 4% to 87,079 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    10/3/25 4:00:08 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    EVP, CSO Skule Jeremy sold $196,228 worth of shares (2,105 units at $93.22), decreasing direct ownership by 2% to 90,446 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    9/4/25 4:00:11 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Director Begley Charlene T sold $289,800 worth of shares (3,000 units at $96.60), decreasing direct ownership by 6% to 46,001 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    8/6/25 4:00:45 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    10/7/25 6:30:06 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Nasdaq Inc.

    SCHEDULE 13G/A - NASDAQ, INC. (0001120193) (Subject)

    10/6/25 5:18:36 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    10/6/25 7:18:50 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NASDAQ upgraded by UBS with a new price target

    UBS upgraded NASDAQ from Neutral to Buy and set a new price target of $115.00

    7/25/25 8:52:40 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    NASDAQ upgraded by Redburn Atlantic with a new price target

    Redburn Atlantic upgraded NASDAQ from Neutral to Buy and set a new price target of $91.00

    4/17/25 8:27:31 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

    Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

    4/15/25 12:40:56 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Leadership Updates

    Live Leadership Updates

    View All

    Puro.earth Secures €11 M Series B Financing Led by Nasdaq with Participation from Fortum Innovation & Venturing to strengthen its supplier infrastructure

    HELSINKI, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Puro.earth, a leading carbon-crediting platform for engineered carbon dioxide removal (CDR), today announced it has raised €11 million in a Series B funding round led by Nasdaq with participation from Fortum Innovation & Venturing. Puro.earth will deploy this funding to strengthen the infrastructure that supports its best-in-class certification journey for suppliers. Key initiatives include enabling more frequent issuance of high-integrity carbon removal credits, facilitating offtake agreements, and advancing open integration of digital measurement, reporting, and verification (dMRV) tools. The new investment builds on a period of strong gr

    9/4/25 7:00:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Thomson Reuters Corp to Join the Nasdaq-100 Index® Beginning July 28, 2025

    NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Thomson Reuters Corp (NASDAQ:TRI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX®) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 28, 2025. Thomson Reuters Corp will replace ANSYS, Inc. (NASDAQ:ANSS) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. ANSYS, Inc. will also be removed from the Nasdaq-100 Tech Sector™ Index (NASDAQ:NDXT), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™), the Nasdaq-100 ESG™ Index (NASDAQ:ND

    7/18/25 8:00:00 PM ET
    $ANSS
    $NDAQ
    $TRI
    Computer Software: Prepackaged Software
    Technology
    Investment Bankers/Brokers/Service
    Finance

    Nasdaq Welcomes 142 IPOs in the First Half of 2025

    Highest volume of listings and capital raise in the first half of the year since 2021 Maintained leadership in switches - crossed $3 trillion in market value transferred since 2005 Driving smart policy reforms to improve regulatory processes for public companies NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) announced today that in the first half of 2025, it welcomed 142 listings (IPOs), raising a total of $19.2 billion. A total of 83 operating companies and 59 SPACs listed on Nasdaq during the first six months of 2025, representing an 86% win-rate of Nasdaq-eligible listings in the U.S. market, and extending Nasdaq's leadership to 46 consecutive quarters. In add

    7/1/25 8:05:00 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $AZN
    $NDAQ
    $XLNX
    Financials

    Live finance-specific insights

    View All

    Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

    Baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in 24-hour ambulatory systolic blood pressure compared with placebo Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic blood pressure (SBP) compared with placebo at 12 weeks. Efficacy was observed throughout the 24-hour period, including early morning, when patients with hypertension are at a higher risk of cardiovascular events.1-3 Patients with treatment-resistant hypertension (rHTN) received baxdrostat 2mg or placebo on top of standard of care.

    10/7/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nasdaq to Hold Third Quarter 2025 Investor Conference Call

    NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ: NDAQ) has scheduled its third quarter 2025 financial results announcement.   Who:Nasdaq's CEO, CFO, and additional members of its senior management team  What:Review Nasdaq's third quarter 2025 financial results  When:Tuesday, October 21, 2025 Results Call: 8:00 AM ET   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/. Note: The press release and results presentation for the third quarter 2025 results will be posted on the Nasdaq Investor Relatio

    9/29/25 4:15:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial

    Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine Positive full results from the ​BaxHTN Phase III trial showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo on top

    8/30/25 10:19:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $NDAQ
    $XLNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/12/24 3:53:01 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    SEC Form SC 13G filed by Nasdaq Inc.

    SC 13G - NASDAQ, INC. (0001120193) (Subject)

    11/8/24 10:52:39 AM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13G/A filed by Nasdaq Inc.

    SC 13G/A - NASDAQ, INC. (0001120193) (Subject)

    11/4/24 1:18:47 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance